ESPR - Esperion Therapeutics, Inc.
About Esperion Therapeutics, Inc. (https://www.esperion.com)
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sheldon L. Koenig | President, Chief Executive Officer & Director | 1966 | $1,427,583 USD |
| Benjamin Halladay | Chief Financial Officer | 1986 | $755,083 USD |
| Benjamin O. Looker | Corporate Secretary, Chief Legal & Corporate Affairs Officer | 1982 | $696,350 USD |
| John Harlow | Chief Commercial Officer | 1976 | $582,940 USD |
| Betty Jean Swartz | Chief Business Officer | – | – |
| Glenn Brame | Chief Technical Operations Officer | 1957 | – |
| LeAnne Bloedon | Vice President & Head of Development | – | – |
| Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development | – | – |
| Tiffany Aldrich | Associate Director of Corporate Communications | – | – |